BioCentury
ARTICLE | Company News

EntreMed transfers its angiostatin, endostatin rights

February 4, 2004 8:00 AM UTC

ENMD transferred to Alchemgen (Houston, Texas) and to Children's Medical Center Corp. (Boston, Mass.) all rights to its endostatin and angiostatin therapeutic protein programs. Alchemgen will have rights in Asia, while Children's will have rights in the rest of the world. ENMD will receive an upfront and a future cash payment plus royalties. ENMD will receive 20% of the proceeds from any future license that Children's grants related to the products. ...